Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE WuXi PharmaTech
SHANGHAI, Aug. 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of Walter Teh-Ming Kwauk as an independent director to the Board of Directors. Mr. Kwauk will serve on the Audit Committee.
Mr. Kwauk is currently a senior consultant at Motorola Solutions (China) Co., Ltd. He serves as a director of Thunder Power Co. Ltd.; Sinosoft Technology Group Ltd., of which he serves as chairman of the audit committee; China Fordoo Holdings Ltd., of which he serves as chairman of the audit committee; and several private companies. He was formerly a director of Alibaba.com Ltd. Mr. Kwauk worked for KPMG from 1977 to 2002 and held a number of senior positions, including the general manager of KPMG's joint venture accounting firm in Beijing, the managing partner in KPMG's Shanghai office, and a partner in KPMG's Hong Kong office. He is a member of the Hong Kong Institute of Certified Public Accountants. Mr. Kwauk received a B.S. and a licentiate's degree in accounting from the University of British Columbia.
"I am very pleased to join the board of WuXi PharmaTech, a company well-known as a leader in pharmaceutical R&D services," said Mr. Kwauk. "I look forward to working with the other board members to help WuXi grow."
"We are delighted to have the benefit of Walter's experience in corporate governance and in accounting and auditing matters," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "With his help, WuXi will continue to advance in its mission to build a comprehensive, integrated open-access R&D services platform."
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For further information please contact:
Director of Investor Relations
Associate Director of Corporate Communications
©2012 PR Newswire. All Rights Reserved.